Amphastar Pharmaceuticals (AMPH) 44th Annual J.P. Morgan Healthcare Conference summary

Strategic direction, business model, and integration

• Operates a fully integrated model with in-house R&D, manufacturing, and marketing, supporting both internal development and strategic acquisitions.

• Maintains full control over quality and compliance across all stages, with vertically integrated operations for flexibility and scalability.

• Dual growth strategy: internal product development and targeted acquisitions, such as Baqsimi and facilities in the US and France.

• Expanded international footprint to over 26 countries, leveraging acquisitions to support proprietary launches.

• Focuses on high-quality, high-efficiency, and high-technology products for competitive advantage.

Growth strategy, financial performance, and market strategy

• Revenue grew from $295M in 2018 to $732M in 2024, with adjusted net income margin rising to 27.4%.

• Annual EPS increased from $0.64 in 2020 to $4.5 in 2024, with a 20% CAGR in revenue and 57% CAGR in adjusted EPS.

• R&D investment reached $351M over five years, with annual R&D expenses rising and expected to increase further.

• 2026 revenue growth forecast revised to mid-single digit to low double digits, driven by new launches and expanded sales.

• Strategic withdrawal from unprofitable international Baqsimi markets to improve margins.

Pipeline evolution, R&D highlights, and innovation

• By 2026, proprietary and biosimilar products are projected to comprise 85% of the pipeline, up from 37% in 2021.

• Proprietary pipeline includes intranasal epinephrine, reformulated Primatene Mist, and several in-licensed NCEs.

• Promising peptide and biologics pipeline targets oncology, ophthalmology, endocrinology, and rheumatology.

• AMP-109 demonstrated >99% tumor inhibition in preclinical pancreatic cancer models; AMP-110 is a fully synthetic corticotropin analog with reduced impurity and viral risk.

• Proprietary delivery technologies include intranasal and metered dose inhaler platforms, supporting innovation in drug administration.